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Asthma is a complex, multifactorial disease that is underpinned by airway inflammation. A variety of cytotoxic substances are released into the air-
way from infiltrating inflammatory cells, especially the eosinophil. These cytotoxic substances, including reactive oxygen metabolites, produce dam-
age to the airway epithelium, a histologic feature of chronic asthma. Damage to the airway epithelium, in turn, is thought to be a major factor
responsible for the development of airway hyperreactivity, a hallmark of asthma. One notable molecular target for novel antiasthmatic drugs is the
cyclic AMP-specific phosphodiesterase (PDE) or PDE IV. This isozyme is the predominant form of cyclic nucleotide PDE activity in inflammatory
cells. Thus, in view of the putative role of cyclic AMP as an inhibitory second messenger in these cells, PDE IV inhibitors have been shown to sup-
press inflammatory cell activity. The purpose of the present experiments was to examine the effect of the PDE IV inhibitor, R-rolipram, on three key
functions of the guinea pig eosinophil: a) superoxide anion (°O) production, b) adhesion to human umbilical vein endothelial cells (HUVECs), and c)
infiltration into the airway. R-rolipram-elevated eosinophil cyclic AMP content (EC50= 1.7 pM) and inhibited fMLP-induced °2 production in a con-
centration-dependent manner (IC50=0.3 pM). In contrast, neither siguazodan, a PDE IlIl inhibitor, nor zaprinast, a PDE V inhibitor, had an appreciable
effect. R-rolipram (30 pM) also reduced by 25 to 40% the adhesion of eosinophils to HUVECs stimulated with phorbol myristate acetate or tumor
necrosis factor-a, particularly under conditions in which both cell types were simultaneously exposed to the PDE IV inhibitor. Again, siguazodan and
zaprinast had little or no effect. Finally, pretreatment of conscious guinea pigs with R-rolipram (1-10 mg/kg, intragastric) produced a dose-dependent
inhibition of antigen-induced eosinophil infiltration into the airway. Thus, by virtue of their ability to modify eosinophil function at several levels, PDE
IV inhibitors may reduce epithelial cell damage associated with asthma. - Environ Health Perspect 102(Suppl 10):79-84 (1994)
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Introduction
Asthma is a complex, multifactorial
inflammatory disease of the airways (1,2).
Both acute and chronic inflammatory
processes lead to the two hallmarks of
asthma, airway obstruction and airway
hyperreactivity (2,3). Various mediators
released from a number of inflammatory
cells produce bronchoconstriction, pul-
monary edema, and mucus secretion (3),
three acute and reversible changes that
result in airway obstruction. As chronic
inflammatory processes proceed unchecked,
more insidious and perhaps irreversible
changes in airway architecture develop
(4,5). Chief among these changes is loss of
the airway epithelium (5). It is believed
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that the loss ofthe airway epithelium leads
to airway hyperreactivity by exposing
subepithelial sensory nerve endings to the
external environment (6,7). Consequently,
noxious environmental stimuli more easily
activate these nerve endings to cause
antidromic release of bronchoconstricting
neuropeptides (e.g., substance P) from C-
fibers via an axon reflex (6,7).
The inflammatory cell primarily respon-
sible for damaging the airway epithelium is
the eosinophil (Figure 1). Eosinophils are
recruited into asthmatic airways and acti-
vated by a variety of lipid mediators (e.g.,
leukotriene B4, platelet activating factor)
and cytokines (e.g., tumor necrosis factor-a,
interleukin-5) (3,8). Activated eosinophils
release both proinflammatory and cytotoxic
substances (3,8,9). In particular, these cells
release cationic proteins (e.g., major basic
protein, eosinophil cationic protein) and
reactive oxygen metabolites (e.g., superox-
ide, singlet oxygen) (8-10). Hypothetically,
these substances act in concert to destroy
epithelial cell membranes. Indeed, the pro-
posed role of eosinophil-derived reactive
oxygen intermediates in producing epithelial
damage has been supported by several in
vitroand in vivostudies in both animals and
humans (10-14).
Recently, cyclic nucleotide phosphodi-
esterases (PDEs), a family of enzymes that
metabolize cyclic AMP and cyclic GMP,
have received considerable attention as
molecular targets for novel antiinflamma-
tory and antiasthmatic drugs (14,15). This
interest has been fueled by the recognition
that, in general, cyclic AMP suppresses the
activity of immune and inflammatory cells
(15,16). Thus, by virtue oftheir ability to
elevate cyclic AMP content, PDE inhibitors
possess antiinflammatory activity. Of par-
ticular interest as a drug target is the cyclic
AMP-specific PDE, also known as PDE IV
(15,16). This isozyme is the predominant
PDE present in most inflammatory cells
(15,16), including the eosinophil (17,18).
Consequently, PDE IV inhibitors suppress
the activity ofeosinophils, as evidenced by
their ability to reduce the generation of
superoxide anion and H202 (17,18). In
addition to the direct effect of PDE IV
inhibitors on eosinophils, these com-
pounds may suppress eosinophil function
indirectly by producing a general reduction
in the formation of lipid mediators and
cytokines (15,16), thus inhibiting
eosinophil migration and activation. Taken
collectively, this information suggests that
PDE IV inhibitors may be beneficial in
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Figure 1. Role of the eosinophil in oxidant-induced
lung injury and airway hyperreactivity associated with
asthma. Growth and differentiation factors (e.g., inter-
leukin-5) stimulate the formation of eosinophils from
pluripotential stem cells. Eosinophils are released into
the blood where they are carried to the pulmonary cir-
culation. Various lipid mediators (e.g., leukotriene B4,
platelet-activating factor) and cytokines (e.g., inter-
leukin-5, TNFa) are released from immune and inflam-
matory cells in the lung. These substances cause
eosinophils to adhere to the pulmonary endothelium
and, subsequently, promote the migration ofthese cells
to the airway epithelium. Activated eosinophils gener-
ate reactive oxygen metabolites and release cationic
proteins, both of which damage the airway epithelium.
Damage to the epithelium exposes underlying nerve
endings to noxious stimuli in the external environment.
This activates afferent sensory nerve endings, leading
to reflex bronchoconstriction. This hypothetical sce-
nario could contribute to airway hyperreactivity, a hall-
mark of asthma.
reducing eosinophil-induced lung injury
associated with chronic asthma.
The present studies were conducted to
define the effects ofisozyme-selective PDE
inhibitors on eosinophil function in vitro
and in vivo. Specifically, we examined the
effects of rolipram, a PDE IV inhibitor
(19), siguazodan, an inhibitor ofthe cyclic
GMP-inhibited PDE (PDE III) (20), and
zaprinast, an inhibitor of the cyclic GMP-
specific PDE (PDE V) (21) on the follow-
ing eosinophil functions: a) superoxide
generation, b) endothelial cell adhesion,
and c) infiltration into the airways.
Methods
Eosinophil IsolationandPurification
Peritoneal eosinophils were elicited by a
modification of the procedure described by
Gleich and Loegering (22). Male guinea
pigs (Hartley, Hazelton Labs, Denver, PA)
were injected with 1 ml of sterile horse
serum weekly for 4 to 6 weeks prior to use.
Animals were anesthetized with a mixture of
88 mg/ml ketamine and 12 mg/ml of
xylazine (0.4 ml/kg) 24 hr after an injection
ofhorse serum. After the induction ofanes-
thesia, the peritoneal cavity waslavagedwith
50 ml ofwarm sterile saline (0.9%) using a
14-gauge catheter, and the fluid collected in
50-ml plastic conical centrifuge tubes. The
guinea pigs were allowed to recover from the
anesthesia and could be used again after a 2-
week rest period. No difference in either the
recovery ofcells or in the responsiveness of
these eosinophils was noted if the animals
were lavaged repeatedly.
To isolate eosinophils, the lavage fluid
was centrifuged (400g, 10 min), the result-
ing pellet was resuspended in 35 ml of
phosphate-buffered saline (PBS) and then
underlayed with 10 ml of isotonic Percol
(1.075 g/ml). This suspension was cen-
trifuged for 30 min at 300g. The pellet,
containing mainly eosinophils and erythro-
cytes, was washed in PBS; the erythrocytes
were lysed with distilled water (9 ml); and
isotonicity was then restored by the addi-
tion of 10 x PBS (1 ml). Eosinophils were
resuspended in RPMI 1640 medium with
20% fetal bovine serum and incubated
overnight at 37°C in a humidified 5%
CO2 incubator. The next day cells were
washed and resuspended in PBS for deter-
mination ofcell viability and purity.
SuperoxideAnionProduction
Superoxide anion (O°) production was
determined by a modification of the
microassay developed by Pick and Mizel
(23). Purified eosinophils (viability >95%
and purity >90%) were resuspended in
Earle's balanced salt solution (EBS) with
20 mM HEPES buffer, pH 7.4, and 0.1%
gelatin at a concentration of 1 to 2x 106
cells/ml. Eosinophils (105 cells per well)
were added to a 96-well plate and incu-
bated for 1 hr at 370C. Eosinophils were
pretreated with various concentrations of
PDE inhibitors for 10 min prior to the
start ofthe reaction. The reaction was initi-
ated by the addition offMLP (30 nM) and
cytochrome c (160 jiM) in the absence or
presence of 60 U ofsuperoxide dismutase.
Cytochrome c reduction was monitored on
a Dynatech (Chantilly, VA) MR 7000
plate reader at 550 nm with a 630-nm ref-
erence at several time points after the addi-
tion of fMLP. The production OfO2 was
determined as the difference in absorbance
between wells in the absence and presence
of superoxide dismutase. Results are
expressed as a percent ofthe control rate of
cytochrome c reduction using the extinc-
tion coefficient of21 x103 M-lcm-1. Since
the maximum inhibition ofO2 generation
produced by PDE IV inhibitors was 60%,
the potencies of R- and S-rolipram were
determined by the concentration that pro-
duced 30% inhibition (IC30) ofthe fMLP-
stimulated rate. These values were
calculated by linear interpolation using the
mean response obtained from three to four
experiments.
MeasurementofCyclicAMP
Accumulation inGuineaPig
Eosinophils
Cultured guinea pig eosinophils were resus-
pended in EBS with 20 mM HEPES, pH
7.4, + 0.1% gelatin at a cell concentration
of 3x1i07 cells/ml. Aliquots (100 pl) of
cells were incubated with various concen-
trations of PDE inhibitors for 5 min at
37°C prior to the start ofthe reaction. The
reaction was initiated by the addition of
PGE2 (10 pM) and continued for an addi-
tional 5 min. Cyclic AMP content was
measured by RIA using commercially avail-
able kits (New England Nuclear, Boston,
MA). Data were expressed as the increase
in cAMP content/106 cells over that seen
with PGE2 alone.
EosinophilAdhesion
The experimental procedures employed in
these studies were based on the method
described by Schleimer and co-workers
(24). Human umbilical vein endothelial
cells (HUVECs), obtained from Cell
Systems (Seattle, WA), were grown to
confluence in Cell Systems (CS) complete
medium on gelatin-coated 24-well plates.
All experiments were conducted using cells
passaged four times. Eosinophils were iso-
lated from guinea pigs by peritoneal lavage
as outlined above. Eosinophils were labeled
in a volume of 0.5 ml PAG buffer (Pipes,
25 mM; NaCl, 110 mM; KCI, 5 mM;
human serum albumin, 0.003%; and glu-
cose, 0.1%, pH 7.4) with 0.4 m; Ci sodium
51Cr chromate by incubation at 37°C for
60 min. The cells were washed four times
in a large volume ofPAG buffer and finally
resuspended in PAGCM (PAG buffer plus
CaCl2, 1 mM and MgCl2, 1 mM) at
1 x 106 cells/ml.
Phorbol myristate acetate (PMA; 0.1
pM) or tumor necrosis factor-a (TNFa,
1000 U/ml) was added to the HUVECs
while in CS medium and incubated in a
CO2 incubator at 37°C for 4 hr. After the
4-hr incubation, the medium containing
the stimulant was removed completely and
the cells were rinsed twice with warm
PAGCM buffer. A total of0.5 ml ofwarm
PAGCM buffer containing 0.1 x 106_
labeled eosinophils was added to each well.
The HUVECs and eosinophils were incu-
bated at 37°C in a CO2 incubator for 30
min and then each well was washed with
PAGCM buffer to remove the unbound
eosinophils. One-halfmilliliter 1 M NaOH
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was added to each well to dissolve the cells.
The radioactivity present in the dissolved
cells was measured using a gamma counter.
Three separate incubation conditions
with the PDE inhibitors were used in the
adhesion experiments:
* The PDE inhibitor was added to the
HUVECs at the same time as PMA or
TNFoc and allowed to incubate with
the TNFax or PMA for 4 hr. The PDE
inhibitor was then washed out of the
HUVECs and the adhesion assay per-
formed as outlined above.
* The PDE inhibitor was added to the
labeled eosinophils and incubated for
30 min at 37°C. The cells were washed
twice with buffer, added to the stimu-
lated HWVECs, and the adhesion assay
was performed as outlined above.
* The PDE inhibitor was added to the
TNFax- or PMA-stimulated HUVECs
just before the labeled eosinophils were
added and the adhesion assay was per-
formed as outlined above, with the PDE
inhibitor present during the entire time.
PhosphodiesteraseAssay
The ability of compounds to inhibit
human recombinant PDE IV activity was
assessed as described previously (25).
Antigen-induced Bronchoconstriction
andEosinophil Infiltration
The activityofR-rolipram was examined in a
model ofthe early-phase/late-phase response
to antigen as described previously (26). Male
Hartley guinea pigs, sensitized to ovalbumin
(OA), were pretreated with R-rolipram (1, 3,
or 10 mg/kg, ig) orvehicle (polyethylene gly-
col) 1 hr before antigen challenge and chlor-
pheniramine (0.1 mg/kg, sc) 15 min before
antigen challenge. The animals were placed
into a two-chamber whole-body plethysmo-
graph connected to a respiratory analyzer to
determine specific airway conductance
(sGaw) by a previously described method
(26). An aerosol ofa 1% solution ofOAwas
delivered for 10 sec, and pulmonary function
was monitored for 10 min. Results were cal-
culated as percent change in sGaw from
baseline readings taken just prior to antigen
challenge. Twenty-four hours after antigen
challenge, bronchoalveolar lavage was carried
out on the animals to document inflamma-
tory cell (predominandy eosinophils) infiltra-
tion into thelungs (26).
Results
Effects onEosinophilActivation
Treatment of cultured eosinophils with
either R-rolipram (10 pM) or the nonselec-
Table 1. Effect of R-rolipram, siguazodan, and 3-
isobutyl-1-methylxanthine on cyclic AMP accumulation
and 0° generation in guinea pig eosinophils.a
Cyclic AMP
accumulation, O2 production,c
6
2
Inhibitor pmole/10 cells % inhibition
None 0.48 ± 0.05
IBMX, 100 pM 2.65 ± 0.25* 54.8 ± 6.3*
R-rolipram, 10 pM 5.76 ± 1.16* 58.4 ± 18.1*
Siguazodan, 100 pM 0.66 ± 0.04 1.4 ± 4.9
IBMX, 3-isobutyl-1-methylxanthine. aAll values repre-
sent the mean ± SE. bElevation of cyclic AMP content
in the presence of 10 pM PGE2 (n=4). Clnhibition of
fMLP-induced 0° production (n=3-4) *p<0.05.
tive PDE inhibitor, 3-isobutyl-1-methyl-
xanthine (100 pM), increased cyclic AMP
content and suppressed fMLP-induced O0
production (Table 1). In contrast, the PDE
III inhibitor, siguazodan (100 pM), or the
PDE V inhibitor, zaprinast (10 pM; not
shown), had little or no effect on either
parameter. The effects of rolipram were
concentration dependent and R-rolipram
was 3-fold more potent than S-rolipram as
a PDE IV inhibitor (IC50=0.31 ± 0.09 vs
1.10 ± 0.02 pM, n=4) and 10-fold more
potent as an inhibitor of 01 production
(IC50=0.3 vs 2.0 pM; n=4) or as a stimu-
lator of cyclic AMP accumulation
(EC50=2 pM vs 20 pM; n=4).
To determine if other PDE IV
inhibitors would inhibit eosinophil activa-
tion, 19 structurally diverse PDE IV
inhibitors were evaluated for their ability to
inhibit recombinant human PDE IV and
suppress fMLP-induced 01 production. A
strong rank-order correlation was demon-
strated between the potencies of com-
pounds as PDE IV inhibitors and their
potencies as inhibitors ofeosinophil activa-
tion (Spearman's Rho=0.85, p<0.001).
Similarly, a strong correlation existed
between the absolute potencies of these
compounds as inhibitors ofPDE IV versus
their potencies against eosinophil activa-
tion (r =0.68,p<0.001).
Effects onEosinophilAdhesion
Both PMA (0.1 pM) and TNFX (1000
U/ml) markedly stimulated adhesion of
guinea pig eosinophils to HUVECs. R-
rolipram (10 or 30 pM) significantly inhib-
ited the PMA-induced increase in adhesion
only when both the eosinophils and
HUVECs were exposed to the inhibitor
(Figure 2). Siguazodan (30 pM), a selective
PDE III inhibitor, had no effect on guinea
pig eosinophil adhesion to HUVECs in
any of the three incubation conditions
(Figure 2). Similarly, zaprinast (30 pM), a
0
100-
3jxM 10 ItM 30 iM 30 ZMI
Rollpram Siguazodan
Figure 2. Effect of R-rolipram (3, 10, and 30 pM) or
siguazodan (30 pM) on PMA (0.1 pM)-stimulated adhe-
sion of guinea pig eosinophils to human umbilical vein
endothelial cells (HUVECs). Three different protocols
were employed: a) exposure of HUVECs only with the
POE inhibitor for 4 hr followed by washout (open bars);
b) exposure of eosinophils only with the POE inhibitor
for 30 min followed by washout (hatched bars); c)
exposure of HUVECs and eosinophils with the POE
inhibitor throughout the adhesion assay (solid bars).
Data represent the mean ± SE of six experiments.
*p< 0.05.
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Figure 3. Effect of R-rolipram (3, 10 and 30 pM) or
siguazodan (30 pM) on TNFa (1000 U/ml)-stimulated
adhesion of guinea pig eosinophils to human umbilical
vein endothelial cells (HUVECs). Three different proto-
cols were employed: a) exposure of HUVECs only with
thePDE inhibitor for 4 hr followed by washout (open
bars); b) exposure of eosinophils only with the POE
inhibitor for 30 min followed by washout (hatched
bars); c) exposure of HUVECs and eosinophils with the
POE inhibitor throughout the adhesion assay (solid
bars). Data represent the mean ± SE of six experi-
ments. *p<0.05.
selective PDE V inhibitor, was without
effect on PMA-induced stimulation of
adhesion (data not shown).
R-rolipram (30 pM) significantly inhib-
ited TNFoc-stimulated adhesion of guinea-
pig eosinophils to HUVECs in all three of
the pretreatment conditions (Figure 3). The
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degree of inhibition using the three proto-
cols ranged from 25 to 40%, with cotreat-
ment of eosinophils and HUVECs giving
the greatest inhibitory effect. Siguazodan
(30 pM) also inhibited the adhesion of
guinea pig eosinophils to HUVECs, but
only when the cotreatment protocol was
used. Zaprinast (30 pM) was without effect
on TNFa-induced stimulation ofadhesion
using any of the three treatment protocols
(data not shown).
Effects onAntigen-induced
Bronchoconstriction and
Eosinophil Infiltration
In vehicle-treated guinea pigs, aerosol OA
produced a maximal decrease of 64% of
baseline sGaw (Figure 4, top panel).
Intragastric administration ofR-rolipram (1,
3, or 10 mg/kg) 1 hr before antigen chal-
lenge inhibited the bronchospasm in a dose-
dependent manner. In the same animals, the
OA challenge markedly increased total
leukocyte number, particularly eosinophils,
as assessed by 24-hr bronchoalveolar lavage
(Figure 4, bottom panel). Normal cell num-
bers recovered in unchallenged animals aver-
aged 8.0 ± 1.0 x 106, ofwhich 6 to 10%
were eosinophils (not shown). Similar to its
effect on antigen-induced bronchoconstric-
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Figure 4. Effect of R-rolipram on OA-induced bron-
choconstriction in, conscious guinea pigs (top panel)
and on subsequent airway eosinophil influx (bottom
panel) as measured by bronchoalveolar lavage 24 hr
after the OA challenge. R-Rolipram (1, 3, or 10 mg/kg,
ig) was administered 1 hr before aerosol OA challenge
(1% for 10 sec). Data represent the mean ± SE of six
experiments *p<0.01, analysis ofvariance, Dunnet's t-
test.
tion, R-rolipram substantially reduced
eosinophil influx into the lung in a dose-
dependent manner. R-rolipram also pro-
duced a dose-dependent inhibition
(29-48%) oftotal leukocyte infiltration.
Discussion
The role ofeosinophil-derived reactive oxy-
gen metabolites in producing damage to
the airway epithelium has been recognized
as a major factor in the pathophysiology of
asthma (8-11,14). Consequently, drugs
that modify eosinophil production,
trafficking, or activation should be ofuse in
the treatment ofthis disease. Isozyme-selec-
tive PDE IV inhibitors, typified by
rolipram, represent one such class ofdrugs
(15,16). These agents inhibit the activa-
tion of a variety of inflammatory cells,
including the eosinophil (15-18). The pre-
sent studies were conducted to explore the
potential eosinophil-suppressant effects of
PDE IV inhibitors. Specifically, we deter-
mined the effect ofrolipram on the follow-
ing eosinophil functions: a) fMLP-induced
O° generation, b) PMA- and TNFa-
induced endothelial cell adhesion, and c)
antigen-stimulated migration into the air-
way.
Production of O2 from fMLP-stimu-
lated guinea pig eosinophils was inhibited
strongly by rolipram and 3-isobutyl-1-
methylxanthine, a nonselective PDE
inhibitor, but not by siguazodan or zapri-
nast, selective inhibitors of PDE III and
PDE V, respectively. Several lines of evi-
dence suggest that the inhibitory effect of
rolipram was due to inhibition ofPDE IV.
First, the effect ofrolipram on 02 produc-
tion was accompanied by an increase in
cyclic AMP accumulation. Second, similar
to the enantioselectivity ofrolipram against
the catalytic activity of human recombi-
nant PDE IV, R-rolipram was 10-fold more
potent than S-rolipram with regard to both
inhibition of 02 production and stimula-
tion ofcyclic AMP accumulation in intact
eosinophils. Third, an excellent correlation
was demonstrated between the potencies of
19 compounds for inhibition of human
recombinant PDE IV and their potencies
as inhibitors offMLP-induced 02 produc-
tion. These results support and extend pre-
vious reports indicating that PDE IV
inhibitors reduce basal and opsinized
zymosan-induced H202 and O2generation
from guinea pig eosinophils (17,18).
In addition to its regulatory role in
eosinophil function, cyclic AMP also alters
endothelial cell function. Specifically, ele-
vation of cyclic AMP content inhibits
TNFa-induced expression of the adhesion
molecules, endothelial leukocyte adhesion
molecule (ELAM or e-selectin), and vascu-
lar cell endothelial molecule-I (VCAM-1),
but not intercellular adhesion molecule-I
(ICAM-1) (27). Moreover, like the
eosinophil, endothelial cells contain PDE
IV as their predominant cyclic AMP-
metabolizing enzyme (28,29). Thus, we
hypothesized that PDE IV inhibitors could
interfere with the adhesion of eosinophils
to endothelial cells by acting at either, or
both, cell types. Indeed, the results indicate
that rolipram, but not siguazodan or zapri-
nast, attenuated both PMA- and TNFax-
induced adhesion ofguinea pig eosinophils
to HUVECs. Interestingly, the inhibitory
effect of rolipram depended on the stimu-
lus used. In cells stimulated with PMA,
rolipram was active only when both the
eosinophils and HUVECs were exposed to
the inhibitor. In contrast, eosinophil adhe-
sion to TNFoc-stimulated HUVECs was
inhibited if either the eosinophils or the
endothelial cells were exposed to rolipram
individually, although an even greater
effect was observed ifboth cells were incu-
bated with the inhibitor. The maximum
inhibitory effect of rolipram in these stud-
ies was moderate, ranging from 25 to 40%.
It is possible, however, that more pro-
nounced inhibitory effects would be pro-
duced under conditions whereby adenylyl
cyclase activity in endothelial cells and
eosinophils is elevated, e.g., in vivo under
the influence ofcirculating catecholamines
or locally released prostanoids (30,31).
Such a result would be predicted based
upon the synergistic interactions between
PDE inhibitors and adenylyl cyclase activa-
tors in these cells (18,29).
In addition to its effects in in vitro set-
tings, rolipram altered eosinophil function
in vivo. Specifically, rolipram substantially
reduced the influx of eosinophils into the
airway that occurred over a 24-hr time
period after aerosol administration of anti-
gen to sensitized guinea pigs. Although the
precise mechanism by which rolipram
exerts this effect was not determined, sev-
eral proposals can be made based upon a
variety of in vitro actions of PDE IV
inhibitors. For example, PDE IV inhibitors
suppress mast cell degranulation (32) and
may thus reduce the generation of chemo-
tactic lipid mediators (e.g., leukotriene B4,
platelet activating factor) in response to
antigen challenge. PDE IV inhibitors also
have been shown to reduce TNFax genera-
tion (33) and antigen-driven IL-5 produc-
tion (34). TNFa is believed to be critical
in the recruitment and activation of
eosinophils (35), whereas IL-5 is a major
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eosinophil growth and differentiation factor
(36). Finally, as demonstrated in the pre-
sent study, rolipram has a direct inhibitory
effect on eosinophil adhesion to endothe-
lial cells. Any of these effects, individually
or collectively, could account for the ability
of PDE IV inhibitors to prevent antigen-
induced eosinophil influx into the airways.
In summary, eosinophils have a crucial
role in mediating oxidant-induced lung
injury in asthma. Thus, agents that sup-
press eosinophil function may have a major
impact on the morphologic changes in the
airway that occur as a consequence oflong-
standing asthma. Phosphodiesterase IV
inhibitors represent one class ofagents that
modify eosinophil function at several
levels, ranging from a direct inhibitory
effect on eosinophil activation to a broad
suppression of eosinophil trafficking into
sites ofinflammation. As such, these agents
represent a unique and exciting approach
to the therapy ofasthma.
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